The rapidly escalating COVID-19 pandemic has highlighted the need for novel antiviral strategies, and the extreme urgency of situation suggests that repurposing existing therapeutics (particularly those with an established safety profile and a scalable manufacturing processes) is the most efficient development strategy.
Bold Therapeutics’ BOLD-100 is a first-in-class anti-resistance small molecule therapeutic currently in clinical development for some of the most difficult-to-treat cancer indications.
Recent literature suggests BOLD-100 may have surprising utility as an antiviral agent.
Bold Therapeutics does not currently have the expertise or resources to pursue this project in a relevant timeframe and is urgently seeking a development partner and/or institutional investors interested in this unique solution.
Extensive worldwide patent protection including composition of matter, method of use, and manufacturing process through mid to late 2030s.
In-process adaptation from Bold Therapeutics’ existing oncology focus.
COVID-19 is a life-threatening condition with no approved therapies.
Needed: preliminary evidence that suggests BOLD-100 may improve patient outcomes.
E. Russell McAllister
President and Chief Executive Officer
Executive Vice President, Clinical Development
Bold Therapeutics Inc.
850 W Hastings St, Ste 515
Vancouver, BC V6C 1E1
1) Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor GRP78 binding site prediction [published online ahead of print, 2020 Mar 10]. J Infect. 2020;S0163-4453(20)30107-9. doi:10.1016/j.jinf.2020.02.026
2) Chu H, Chan CM, Zhang X, et al. Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. J Biol Chem. 2018;293(30):11709–11726. doi:10.1074/jbc.RA118.001897
3) Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell's response to stress. Life Sci. 2019;226:156–163. doi:10.1016/j.lfs.2019.04.022
4) Reid SP, Shurtleff AC, Costantino JA, et al. HSPA5 is an essential host factor for Ebola virus infection. Antiviral Res. 2014;109:171–174. doi:10.1016/j.antiviral.2014.07.004
5) Siu KL, Chan CP, Kok KH, Woo PC, Jin DY. Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1. Cell Biosci. 2014;4(1):3. Published 2014 Jan 13. doi:10.1186/2045-3701-4-3
6) Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One. 2009;4(12):e8342. Published 2009 Dec